The Gout Therapeutics Market is Segmented by Drug Class (Xanthine Oxidase Inhibitors, Uricosurics, Recombinant Uricase and More), by Route of Administration (oral and Injection), Application (Acute Gout, Chronic Refractory Gout and More), and Geography (North America, Europe, Asia-Pacific and More). The Report Offers the Value (in USD Million) for the Above Segments.

Snapshot img

The gout therapeutics market is projected to grow by USD 2.69 billion with a CAGR of 14%, during the forecast period 2020 to 2025.

The market research report provides valuable insights into the post-COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers market segmentation by drug class (NSAIDs, urate-lowering agents, corticosteroids, and colchicine) and geography (North America, Europe, Asia, and ROW).

The gout therapeutics market report also offers information on several market vendors, including AstraZeneca Plc, Avion Pharmaceuticals LLC, Cadila Healthcare Ltd., Hikma Pharmaceuticals Plc, Horizon Therapeutics Plc, Ironwood Pharmaceuticals Inc., JW Pharmaceutical Corp., Selecta Biosciences Inc., Takeda Pharmaceutical Co. Ltd., and Teijin Ltd. among others.

Cadila Healthcare Ltd. - The company offers gout therapeutics products such as US RLD is used to treat and prevent low levels of blood clotting factors. The pharmaceuticals segment represents the business of integrated pharmaceutical operations with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

What will the Gout Therapeutics Market Size be During the Forecast Period?

Get the Gout Therapeutics Market Size Forecast by Download Report Sample

Parent Market Analysis

Technavio categorizes the global gout therapeutics Market 2021-2025 market as a part of the global pharmaceuticals market within the overall healthcare industry. Our research report extensively covers external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the gout therapeutics market during the forecast period.

Gout Therapeutics Market: Key Drivers, Trends, and Challenges

Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Gout Therapeutics Market Driver

One of the key factors driving growth in the gout therapeutics market is the technological advancements in medical imaging.
Advances in the medical imaging field will indirectly increase the percentage of the treatment-seeking population, thereby increasing the penetration rate of drugs.
The various medical imaging methods used for the diagnosis of gout include ultrasound, computed tomography (CT), conventional radiography (CR), magnetic resonance imaging (MRI), X-ray, nuclear medicine, and dual-energy computed tomography (DECT). 
Vendors are also developing 2D, 3D, and 4D equipment in the area of medical imaging. They are developing image workstations that provide 3D skeletal construction images for orthopedics with lower X-ray doses. Such innovations are expected to augment the growth of the market in focus during the forecast period. 

Key Gout Therapeutics Market Challenge

Low physician and patient awareness will be a major challenge for the gout therapeutics market during the forecast period.
Reasons for insufficient gout treatment include a poor patient understanding of the disease and a lack of physician awareness to prescribe targeted treatment plans. 
The lack of awareness related to the disease condition and the therapies available for the treatment of gout, primarily in rural areas, are the major challenges faced by the market in developing countries.
Insufficient health infrastructure, limited awareness, and low health budgets pose a threat to the market in focus on developing countries. Thus, the lack of awareness among people and physicians is posing a threat to the growth of the global gout therapeutics market. 

This gout therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Gout Therapeutics Market Value Chain Analysis

Our In-house experts produce extensive information on the value chain and parent market of the gout therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The Value Chain information provides an end-to-end understanding of product insight and profit and also optimization and evaluation of business strategies. The players across the value chain include selective data and analysis from entire research findings as per the scope of the report.

Which are the Key Regions for the Gout Therapeutics Market?

Get a glance at the market share of various regions Requesting a PDF Sample now!

43% of the market’s growth will originate from North America during the forecast period. The US is the key market for gout therapeutics in N

The global Gout Therapeutics Market size was estimated at USD 3.13 billion in 2024 and is projected to grow at a CAGR of 7.0% from 2025 to 2034.

The Gout Therapeutics Market will grow from USD 2.16 Billion in 2024 to USD 3.58 Billion by 2030 at a 8.80% CAGR.

Global Gout Therapeutics Market valued at USD 3.2 billion, driven by rising gout prevalence, aging population, and advancements in uric acid-lowering therapies for better patient outcomes.

According to Cognitive Market Research, the global Gout Therapeutics market size will be USD 3270 million in 2025. It will expand at a compound annual growth rate (CAGR) of 6.70% from 2025 to 2033.

North America held the major market share for more than 40% of the global revenue with a market size of USD 1209.90 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.2% from 2025 to 2033.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 948.30 million.
APAC held a market share of around 23% of the global revenue with a market size of USD 784.80 million in 2025 and will grow at a compound annual growth rate (CAGR) of 9.4% from 2025 to 2033.
South America has a market share of more than 5% of the global revenue with a market size of USD 124.26 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.4% from 2025 to 2033.
Middle East had a market share of around 2% of the global revenue and was estimated at a market size of USD 130.80 million in 2025 and will grow at a compound annual growth rate (CAGR) of 8.0% from 2025 to 2033.
Africa had a market share of around 1% of the global revenue and was estimated at a market size of USD 71.94 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2025 to 2033.
NSAIDs category is the fastest growing segment of the Gout Therapeutics industry

Market Dynamics of Gout Therapeutics Market

Key Drivers for Gout Therapeutics Market

Rising Incidence of Gout to Boost Market Growth

Gout, a prevalent form of arthritis, has been on the rise globally, particularly among middle-aged and older populations. In 2020, an estimated 55.8 million people (with a 95% uncertainty interval of 44.4–69.8 million) worldwide had gout, with an age-standardized prevalence of 659.3 per 100,000—a 22.5% increase since 1990. The prevalence of gout in 2020 was 3.26 times higher in men than in women and increased with age. By 2050, the number of people living with gout is projected to reach 95.8 million (with an uncertainty range of 81.1–116 million). Contributing factors to this rise include lifestyle choices such as poor diets (particularly those rich in purines), obesity, alcohol consumption, and comorbidities like hypertension and diabetes. As the global population continues to age, the number of individuals at risk for gout is expected to grow, driving the demand for gout treatments..

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00117-6/fulltext/

Increase in Obesity Rates to Boost Market Growth

Obesity is a significant risk factor for gout, as it increases the production of uric acid in the body. In 2022, 2.5 billion adults (aged 18 and older) were overweight, with 890 million living with obesity. That year, 43% of adults were classified as overweight, and 16% were obese. Additionally, 37 million children under the age of 5 were overweight. With the global rise in obesity, particularly in developed nations, the incidence of gout is expected to grow. This trend underscores the increasing need for effective treatments to manage both obesity and the symptoms associated with gout.

https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight/

Restraint Factor for the Gout Therapeutics Market

High Treatment Costs, Will Limit Market Growth

One of the major barriers to the growth of the gout therapeutics market is the high cost of treatment, especially for newer therapies such as biologics and uric acid-lowering drugs. These treatments can be expensive, and the cost of long-term management of gout can be a burden on patients, particularly in low- and middle-income countries. Although generic versions of older drugs have lowered costs, newer medications, especially biologics like pegloticase, remain prohibitively expensive for many patients. This cost barrier limits access to treatment, especially in resource-constrained regions, and may prevent many patients from seeking the necessary care.

Market Trends in Gout Therapeutics Market

Growing Demand for Advanced Therapies

As the global incidence of gout increases, there is a growing demand for more effective and targeted treatment options. This includes uric acid-lowering therapies, biologics, and newer drug formulations designed to improve the management of chronic and severe gout cases. The opportunity lies in the development of medicat...

Gout therapeutics market size is expected to register steady revenue CAGR during the forecast period, key factors are changing lifestyle, rising geriatric population, increase in number of patients suffering from chronic gout, expanding research and development activities, and technological advancement in biologics

U.S. Gout Therapeutics Market size was estimated at USD 2.73 billion in 2024, expanding at a compound annual growth rate (CAGR) of 6.9% from 2025 to 2034.

The global Gout Therapeutics Market size was valued USD 2.61 billion in 2023 and is expected to rise to USD 4.52 billion by 2032 at a CAGR of 6.3%.

The gout therapeutics market is projected to be valued at $4.5 billion in 2024, driven by factors such as increasing consumer awareness and the rising prevalence of industry-specific trends. The market is expected to grow at a CAGR of 6.5%, reaching approximately $8.3 billion by 2034.

The size of the Global Gout Therapeutics Market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 15.50% during the forecast period. The global gout therapeutics market has witnessed steady growth, driven by the rising prevalence of gout, a type of arthritis caused by uric acid accumulation in the joints. Gout primarily affects individuals with high levels of uric acid in their blood, and its symptoms include intense pain, swelling, and inflammation, which can significantly impact quality of life. Key drivers of the market include increasing awareness of gout and its treatment options, advancements in drug development, and the growing adoption of biologics. Common treatment options include nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, corticosteroids, and urate-lowering therapies such as xanthine oxidase inhibitors and uricosuric agents. Biologics, like IL-1 inhibitors, are also emerging as a significant segment in the market. Recent developments include: In March 2022, Atom Bioscience presented the positive results of a randomized double-blind, placebo-controlled Phase 2a clinical trial of ABP-671 to treat chronic gout., In March 2022, the United States Food and Drug Administration approved Strides Pharma's Colchicine tablets USP, 0.6 mg, used for the treatment and prevention of gout.. Key drivers for this market are: Growing Adoption of Biologics and Increasing R&D on Regenerative Medicines, Rising Prevalence of Gout with Increasing Alcohol Consumption; Technological Advancements in Imaging Modalities Improved Understanding of Gout. Potential restraints include: Side Effects of Gout Therapeutic Drugs, High Indirect Costs of Gout Therapeutics. Notable trends are: Antihyperuricemic Agents (Urate-Lowering Drugs) Segment is Expected to Grow with High CAGR Over the Forecast Period in the Gout Therapeutics Market.

The North America Gout Therapeutics report provides a detailed analysis of emerging investment pockets, highlighting current and future market trends. It offers strategic insights into capital flows and market shifts, guiding investors toward growth opportunities in key industry segments and regions.

The size of the Gout Therapeutics Market market was valued at USD 2.70 billion in 2023 and is projected to reach USD 4.13 billion by 2032, with an expected CAGR of 6.25 % during the forecast period. Gout counts as a kind of arthritis associated with high levels of uric acid that lead to joint inflammation and it is characterized by the Gout Therapeutics Market. The market includes drugs including NSAIDs, corticosteroids, colchicines and other urate lowering therapy including XOIs (for instance allopurinol, febuxostat) among others. Growth in this market is attributed to rising incidence of gout due to factors such as; sedentary lifestyle, population aging and chronic diseases including obesity and cardiovascular diseases. Also, constant innovation towards new drugs and customized medicines is increasing the treatment portfolios and establishing the market.

KSA Gout Therapeutics Market is expected to reach $500 Mn by 2030, growing at 7.5% CAGR, driven by increasing prevalence, awareness, and therapeutic advancements.

The global gout therapeutics market is projected to reach USD 8.3 billion by 2033, exhibiting a CAGR of 6.3% during the forecast period (2025-2033). The increasing prevalence of gout, rising geriatric population, and growing awareness about the disease are major factors driving the market growth. Moreover, advancements in treatment options, such as the development of novel therapeutics targeting specific pathways involved in gout, are expected to further fuel the market growth. Key trends in the gout therapeutics market include the increasing adoption of biologics, such as interleukin-1 inhibitors and anti-gout antibody therapies. These therapies offer targeted and effective treatment options, reducing the risk of gout attacks and improving patient outcomes. Additionally, the growing emphasis on personalized medicine and the use of genetic testing to identify individuals at risk of developing gout are expected to shape the future of gout therapeutics. The market is characterized by the presence of several established pharmaceutical companies, including Takeda Pharmaceutical Company, Novartis, AstraZeneca, GlaxoSmithKline, Merck, and Regeneron Pharmaceuticals, among others. These companies are actively involved in research and development to expand their product portfolios and gain a competitive edge in the market. The market is segmented based on application (acute gout and chronic gout), type (non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, corticosteroids, xanthine oxidase inhibitors, and biologics), and region (North America, Europe, Asia Pacific, Middle East & Africa, and South America). North America is expected to dominate the market, followed by Europe and Asia Pacific, due to the high prevalence of gout in these regions and the availability of advanced treatment options.

Europe Gout Therapeutics Market size was estimated at USD 688.26 million in 2024 and is expected to grow at a CAGR of 6.8% from 2025 to 2034.

Get key insights on Market Research Intellect's Gout Therapeutics Market Report: valued at USD 3.5 billion in 2024, set to grow steadily to USD 5.8 billion by 2033, recording a CAGR of 7.2%.Examine opportunities driven by end-user demand, R&D progress, and competitive strategies.

The Gout Therapeutics Market size is expected to reach USD 5.27 billion in 2034 growing at a CAGR of 6.45. The Gout Therapeutics Market report classifies market by segmentation, growth drivers, demand, trend, and forecast insights.

The global Gout Disease Treatment Market size was USD 2681.2 million in 2024. Increasing prevalence of gout and rising awareness about effective treatment options is expected to boost sales to USD 4838.730992 million by 2031, with a Compound Annual Growth Rate (CAGR) of 8.80% from 2024 to 2031.

Saudi Arabia Gout Therapeutics Market valued at USD 15 million, driven by rising gout prevalence, awareness, and innovative therapies like biologics and urate-lowering agents.